Hata and colleagues identify lorlatinib analogs that overcome acquired therapy resistance to current ALK inhibitors and show their efficacy in preclinical models of non-small cell lung cancer bearing compound therapy-resistant ALK alterations.
- Aya Shiba-Ishii
- Ted W. Johnson
- Aaron N. Hata